Pō a Ao Healing Sanctuary

01 · Understanding the medicine

What is Iboga?

Iboga is a Central African shrub (Tabernanthe iboga); ibogaine is its principal psychoactive indole alkaloid and noribogaine is a major active metabolite. Contemporary research has focused mainly on opioid use disorder (OUD), with smaller observational work involving other substance-use problems and psychological symptoms. A systematic review found 24 clinical studies including 705 people, but only a small minority were randomized controlled trials; most were open-label studies, case series, surveys, or case reports 1. Reported reductions in withdrawal symptoms and craving are promising signals, not proof of durable recovery or superiority to established care. In the United States, FDA materials describe ongoing psychedelic-drug development rather than an approved ibogaine medicine 5. NIDA identifies methadone, buprenorphine, and naltrexone as FDA-approved medications for OUD, with lofexidine helping withdrawal symptoms 4.

02 · The science

How it works

Ibogaine and noribogaine act across several systems rather than through one established pathway. Reviews describe modulation of opioid, serotonin, glutamate/NMDA, sigma, and nicotinic acetylcholine targets, while emphasizing that the clinically relevant anti-addictive mechanism remains uncertain 3. Noribogaine may contribute substantially after ibogaine is metabolized. Ibogaine also inhibits cardiac hERG potassium channels, slowing ventricular repolarization and helping explain QT prolongation and arrhythmia risk 2. Mechanistic findings from cells and animals cannot be assumed to predict benefit or safety in a particular person.

03 · Hope, with context

What researchers are exploring

Potential benefit is not a promised outcome. The study population, support, setting, and evidence quality all matter.

Rapid reduction of opioid withdrawal and craving

Small clinical studies and observational reports describe less acute opioid withdrawal and craving after administration. The evidence is heterogeneous, often uncontrolled, and vulnerable to selection, expectancy, and follow-up bias; it does not establish sustained abstinence or replacement of evidence-based OUD care 1.

Early signal; insufficient for clinical efficacy conclusions

Source 1 Source 4

Possible short-term psychological improvement

Some studies report improvements in depressive or trauma-related symptoms and wellbeing, but these findings are secondary, commonly observational, and not adequate to establish treatment for depression, PTSD, or other psychiatric disorders 1.

Preliminary and uncertain

Source 1

Research value for new addiction medicines

Ibogaine's multi-target pharmacology and rapid changes in withdrawal-related measures make it a useful subject for controlled research, including dose-finding and safety studies. A completed Phase 1/2 study record was designed to assess tolerability and proof of concept, not to confer approval 6.

Investigational research rationale, not a proven benefit

Source 3 Source 6

04 · Informed decisions

Safety & medication interactions

Do not start, stop, combine, or taper medicines based on this page. Discuss your complete medication list and health history with your prescriber or pharmacist.

Serious cardiac arrhythmia

QTc prolongation, bradycardia, torsades de pointes, cardiac arrest, and death have been reported. In a 14-person monitored observational study, all had severe transient ataxia and half exceeded a QTc of 500 ms; no torsades occurred in that small, screened sample 2.

Source 2 Source 6

Neurologic and physical impairment

Marked ataxia, dizziness, nausea, vomiting, and prolonged altered consciousness can impair walking, judgment, and ability to respond to an emergency. Neurologic toxicity signals include severe transient ataxia in humans and concerning preclinical findings; the human long-term risk is not well defined [1, 2].

Source 1 Source 2

Psychiatric destabilization

Case reports and trial screening criteria raise concern about agitation, mania, psychosis, suicidality, or persistent perceptual symptoms. People with psychotic or bipolar disorders, significant suicidality, or some severe psychiatric histories have often been excluded from studies, limiting generalizability [2, 6].

Source 2 Source 6

Uncertain product and medical risk

Unregulated preparations may vary in identity and alkaloid content, while serious complications may require immediate cardiac and emergency care. Deaths and severe complications are documented; a retreat setting or supervision claim is not equivalent to a validated medical service [1, 2].

Source 1 Source 2

Interaction considerations

Risk may increase with other QT-prolonging medicines, drugs that slow heart rate, electrolyte disturbances, or medicines and supplements that alter CYP2D6 metabolism. Serotonergic and other psychoactive combinations may also be unpredictable. Clinical studies commonly excluded QT-prolonging or CYP2D6-affecting medicines and screened out many CNS drugs [2, 6]. Do not stop, substitute, or combine prescribed treatment based on this entry; a qualified clinician or pharmacist must review the complete medication and health history.

Explore the Safety Center

05 · The wider story

History, culture & legal context

Iboga and ibogaine should be distinguished. Iboga is part of living Central African cultural and spiritual practices, including Bwiti traditions; those practices have their own knowledge, ethics, and community authority and should not be reduced to a clinical protocol or wellness product 2. Contemporary biomedical studies are separate, mostly small, and conducted in selected adults—often people with OUD who were medically screened. Cultural ceremony, underground treatment, and clinical research are not interchangeable.

Legal context

Legal status varies by jurisdiction and can change. As of the DEA's August 27, 2026 list, ibogaine is a U.S. federal Schedule I controlled substance (drug code 7260) 7. FDA's current public materials describe research and an early-phase noribogaine study, not approval of ibogaine for OUD or any other condition 5. Possession, use, importation, and ceremonial or clinical access may be regulated differently elsewhere; check the current law and regulator in the relevant location.

06 · Beyond the experience

Preparation & integration

Before

There is no validated self-directed preparation or safe universal amount. Research protocols use medical screening, ECG and laboratory assessment, exclusion criteria, observation, and emergency planning; even then, clinically important QTc prolongation and ataxia occurred [2, 6]. This entry does not provide dosing, tapering, washout timing, sourcing, or a combination protocol. Anyone considering participation in research should use a registered study and discuss standard treatment options with a qualified clinician.

After

After any intense altered-state experience, support may include rest, monitoring for delayed physical or psychiatric symptoms, and nonjudgmental follow-up with qualified health professionals. Integration is not a substitute for treatment of OUD, overdose-prevention planning, psychotherapy, or ongoing medical care. New fainting, palpitations, seizure, severe confusion, chest pain, breathing difficulty, or suicidal thoughts require emergency help.

Questions to bring to your care team

What evidence supports ibogaine for my specific condition, and how does it compare with approved or established care?
What cardiac, psychiatric, neurologic, liver, and medication risks could apply to me, and what monitoring and emergency capability are actually available?
Is this a legally authorized research setting with informed consent, independent oversight, and a clear plan for follow-up and ongoing care?

Preparation guide →Integration support →

07 · Follow the evidence

Sources & further reading

Read the original work. Publication is not endorsement, and a source check is not independent clinical review.